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Abstract
Background: Matrix metalloproteases (MMPs) constitute a family of enzymes capable of
degrading different components of the extracellular matrix and are implicated in the invasion of
tumor cells through the basement membrane. Polymorphisms in MMP genes may result in changes
in the expression of MMPs being associated with the development and progression of cancer. We
have investigated the association between three polymorphisms (-1607 1G/2G, +17 C/G and -77
A/G) in the human collagenases MMP1, MMP8 and MMP13 and the risk of development or
progression of lung cancer.
Methods: A hospital-based case-control study was designed including 501 lung cancer patients and
510 controls matched. Genotypes were determined by PCR-RFLP. Results were analyzed using
unconditional logistic regression, Cox's proportional hazard regression, and the Kaplan-Meier
method.
Results: The MMP1 and MMP13 promoter polymorphisms were not associated with lung cancer
risk, while the C/G polymorphism in MMP8 was associated with a statistically significant decreased
risk of developing lung cancer (ORadj = 0.65; 95%CI = 0.45–0.93). The Kaplan-Meier analysis
showed that the polymorphisms in MMP1, MMP8 and MMP13 not seem to modify the overall
survival. Multivariate analysis revealed that MMP1, MMP8 and MMP13 polymorphisms are not
independent prognostic factors for overall survival.
Conclusion: This study suggests that the polymorphism in MMP8 is associated with a decreased
lung cancer risk, which can be used as a prognostic marker in lung cancer.
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Lung cancer constitutes one of the leading causes of death
in industrialized countries, and its incidence is rapidly
growing in developing nations worldwide. Although
tobacco smoke and other environmental pollutants are
responsible for more than 80–90% of the cases in men
[1], it is well established that less than 10–15% of smokers
develop lung cancer, indicating that other factors might
contribute to the development of this disease [2,3]. In this
regard, the availability of the human genome sequence
has revealed the existence of numerous polymorphisms
that affect both coding and non-coding regions [4], which
might contribute to differences in the individual suscepti-
bility to develop cancer [5-7].
One of the main characteristics of cancer cells is their abil-
ity to proliferate, invade the surrounding tissues and
migrate to distant organs and form metastasis, thereby
resulting in the emergence of disseminated metastases,
which remains the primary cause of mortality in cancer
patients [8-10]. Matrix metalloproteases (MMPs) consti-
tute a group with the ability to cleave most components of
the extracellular matrix, including collagen, laminin,
fibronectin, proteoglycans or elastin, among others
[11,12]. The expression of these MMPs by tumor cells
might contribute to increasing the invasive potential of
tumoral cells by allowing the remodeling of the extracel-
lular matrix. In this sense, overexpression of collagenase-
1 (MMP1) and collagenase-3 (MMP13) has been associ-
ated with more aggressive tumors and poor prognosis in
different tumor types [13,14]. Furthermore, MMP1
expression has been found to be an important marker of
metastasis in breast cancer cells, confirming the impor-
tance of MMPs in tumor growth and invasion [13,15].
Polymorphisms in the regulatory regions of MMPs have
been associated with changes in the expression level of
these genes in different human diseases [16-18]. In fact,
the -1607 1G/2G polymorphism in the promoter region
of MMP1 creates an Ets binding site which increases the
promoter activity of this gene [19]. Thus, the 2G allele of
MMP1 has significantly higher transcriptional activity
than the 1G allele and has been associated with an
increased risk of common cancers, including oral, colorec-
tal, renal and head and neck [17,20-22]. Furthermore, in
colorectal and ovarian cancer, the presence of the 2G
allele in the MMP1 gene was significantly associated with
poorer survival of patients with cancer [23,24]. On the
other hand, the -77 A/G polymorphism in the promoter
region of MMP13, which modifies a PEA3 binding site
resulting in reduced transcriptional activity of this gene
[25], might contribute to reduce the risk of developing
cancer. However, most of the epidemiological studies do
not support this biological evidence. Two recent studies
have shown no association between the -77 A/G polymor-
phism and the risk of developing breast and nasopharyn-
geal cancer [26-28]. Finally, although recent studies in
animal models have shown that mutant mice deficient in
MMP8 are more susceptible to develop skin cancer, sug-
gesting that MMP8 has a protective function against
tumor developments [29,30], there are no epidemiologi-
cal studies to analyze the association between polymor-
phisms in the promoter region of MMP8 and the
susceptibility to develop cancer.
In this study, we reasoned that polymorphisms in the reg-
ulatory regions of the three human collagenases (MMP1,
MMP8 and MMP13), affecting the expression level of
these genes, might influence the risk and survival of lung
cancer patients.
Methods
Study subjects
The detailed methods of recruiting participants for this
hospital-based case-control study have been described
elsewhere [31-33]. Briefly, a total of 501 incident cases of
histologically confirmed lung cancer were recruited in two
main hospitals of Asturias in Northern Spain [Cabueñes
Hospital in Gijón (54%) and San Agustín Hospital in
Avilés (46%)], following an identical protocol from Octo-
ber 2000 to April 2006. 510 controls were selected from
patients admitted to participating hospitals for diagnoses
believed to be unrelated to the exposures of interest, indi-
vidually matched to the cases in ethnicity, gender and age
(± 5 years). The main specific pathologies of the final con-
trols selected were: 41.1% inguinal and abdominal her-
nias (ICD-9: 550–553), 32.5% injuries (ICD-9: 800–848,
860–869, 880–897), 8.8% appendicitis (ICD-9: 540), and
13.3% intestinal obstructions (ICD-9: 560, 569, 574). The
study was approved by the ethical committee of the hos-
pitals, and written consent was obtained from each partic-
ipant.
Data collection
Information on known or potential risk factors for lung
cancer was collected personally through computer-
assisted questionnaires by trained interviewers during the
first hospital admission for diagnosis. Structured ques-
tionnaires collected information on age, gender, sociode-
mographic characteristics, recent and prior tobacco use,
and personal and family history of cancer (first-degree rel-
atives) from each participant. A total of 93.8% eligible
cases and 98.5% of eligible controls agreed to participate
in the study and were interviewed. Reasons for eligibility
are: pathology confirmation, residence, reassignments,
and mental handicap. Of the 759 cases and 593 controls
interviewed, 741 (97.6%) cases and 556 (93.8%) controls
provided a blood or buccal cell sample for DNA extrac-
tion. Fifty-five individuals were excluded, seventeen indi-
viduals (5 cases and 12 controls) because of low amountsPage 2 of 12
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ficulties in the genotyping. Thirty seven individuals (26
cases and 11 controls) with missing information in the
questionnaires and 194 cases without matched controls
were also excluded from these analyses. Thus, the final
study population available for this study was 501 cases
and 510 controls, all of whom were Caucasian.
Genotype determination
The polymorphisms in the promoters of MMP genes ana-
lyzed in this study are shown in Table 1. The polymerase
chain reaction (PCR) combined with restriction fragment
length polymorphism (RFLP) was used to determine the
MMPs genotypes. Genomic DNA used for the assay was
extracted from peripheral blood samples (96.5% of total)
or exfoliated buccal cells (3.5% of total) as previously
described [34]. For quality control, genotyping was
repeated randomly in at least 5% of the samples, and two
of the authors independently reviewed all results. A qual-
ity control of 50 blood and mouthwash samples from the
same participants ensured the reliability of genotyping
results of mouthwash samples. In both quality controls
no differences were found. PCR reactions were carried out
in a total volume 10 μl containing 20 ng of genomic DNA,
0.25 mM each dNTPs (Ecogen, Biologia Molecular S.L.),
0.2 units Taq polymerase (Biotools, Inc.) and 2.5 pmol of
each primer in 1 × PCR buffer (Sigma-Aldrich Co.). The
details of primers and PCR conditions used for the ampli-
fication of MMPs are shown in Table 1. For MMP1, the
reverse primer was designed to introduce a recognition
site for the restriction enzyme AluI (New England Biolabs,
Inc.) by replacing a T with a G. A 5 μl aliquot of PCR prod-
ucts was digested overnight at 37°C with 0.4 units of the
indicated restriction enzyme. After overnight digestion,
the products were separated on agarose gels and stained
with ethidium bromide (restriction enzyme are shown in
Table 1). To verify that the data obtained by RFLP was
coincident with the allele sequence, representative frag-
ments were sequenced (data not shown).
Statistical Analysis
Tests for Hardy-Weinberg equilibrium among controls
were conducted using observed genotype frequencies and
a χ2 test with one degree of freedom. Univariate analysis
was first performed to compare the distribution of age and
gender and the frequencies of alleles and genotypes. The
differences in the distribution between cases and controls
were tested using the χ2, Fisher exact, and Mann-Whitney
U-test, where appropriate. The crude odd ratios (ORs)
were calculated by Wolf's method [35]. Multivariate
unconditional logistic regression analysis with adjust-
ment for age, gender, family history of cancer (first-degree
relatives), and pack-years was performed to calculate
adjusted ORs and 95% confidence intervals (CIs). The
survival curves were constructed using the Kaplan-Meier
method, and differences between the groups were tested
by the log-rank method. The multivariate analysis of
probable prognostic factors for survival was performed
using Cox's proportional hazard regression analysis and
relative risk with 95% confidence intervals, with adjust-
ment for variables with statistical significance in univari-
ate analysis. All statistical analyses were performed with
STATA version 8 software. The sample size of our study for
an allele frequency of 13% is enough to detect ORs greater
than 0.65 with 84.5% power assuming a log-additive
model, while for an allele frequency of 28% the power to
detect an OR of 1.24 is 60%. However, the power to detect
an OR greater than 1.00 for 51% allele frequencies is only
5%.
Results
Population Characteristics
The analysis included 501 lung cancer cases and 510 con-
trols from the Caucasian population of Asturias, Northern
Spain. The distributions of age, gender, smoking status,
family history of cancer, histological types and clinical
stages data for the cases among the study subjects are sum-
marized in Table 2. There were no statistically significant
differences among cases and controls in terms of mean
age and gender distributions, suggesting that the fre-
quency matching was adequate. Furthermore, the control
population was consistent with Hardy-Weinberg equilib-
rium for all polymorphisms studied.
We have determined the frequency of 3 polymorphisms
in 3 human collagenases implicated in the degradation of
the extracellular matrix components and basement mem-
branes in lung cancer patients and matching controls in
order to evaluate their association with the risk and the
survival of lung cancer.
Table 1: Details of PCR conditions and RFLPs studied
Gene Polymorphism Primer sequence PCR Conditions Enzyme
MMP1 -16071G/2G (F) TGA CTT TTA AAA CAT AGT CTA TGT TCA
(R) TCT TGG ATT GAT TTG AGA TAA GTC ATA gC
35 cycles: 94°C 30 s, 54°C 30 s, 72°C 30 s AluI
MMP8 + 17C/G (F) CTG TTG AAG GCC TAG AGC TGC TGC TCC
(R) CAT CTT CTC TTC AAA CTC TAC CC
30 cycles: 94°C 45 s, 64°C 45 s, 72°C 1 min DdeI
MMP13 -77A/G (F) GAT ACG TTC TTA CAG AAG GGC
(R) GAC AAA TCA TCT TCA TCA CC
30 cycles: 94°C 30 s, 54°C 30 s, 72°C 30 s BrsIPage 3 of 12
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The distribution of MMP1 genotypes was very similar
between cases and controls, with frequencies of 1G/1G,
1G/2G and 2G/2G genotypes of 25.5%, 49.5% and 25.0%
in cases and 23.3%, 50.8% and 25.9% in controls, respec-
tively. When we evaluated the association between MMP1
genotypes and lung cancer risk (Table 3), we found that
individual with 2G/2G genotype and individual with 1G/
2G or 2G/2G genotype (2G carriers) presented a lack of
association with lung cancer risk (adjusted OR = 1.04;
95% CI = 0.68–1.58 and adjusted OR = 0.99; 95% CI =
0.71–1.40, respectively). When we carried out stratified
analysis by selected variables [see Additional file 1], no
association was found between the MMP1 polymorphism
and lung cancer risk for age, gender, smoking status, and
family history of cancer. However, stratified analysis by
histological types, showed that the MMP1 2G/2G geno-
type potentially tends to increase the risk of developing
small cell lung cancer (adjusted OR = 2.06; 95% CI =
0.94–4.51; P = 0.072) [see Additional file 2].
Analysis of the -77 A/G polymorphism in the MMP13 gene
The frequency of the MMP13 -77G allele for cases and
controls was 0.297 and 0.279 respectively, similar to the
variant allele for MMP1. Similar to the 1G/2G polymor-
phism in the MMP1 promoter, the MMP13 G/G genotype
presented a lack of association with lung cancer risk
Table 2: Characteristics of lung cancer cases and control patients in a Spanish population
Variable Cases (n = 501)
n (%)
Controls (n = 510)
n (%)
Pa
Gender
Male 441 (88.0) 440 (86.3)
Female 60 (12.0) 70 (13.7) 0.406
Age (yrs), mean (SD) 64.7 (11.0) 63.6 (11.2) 0.137
Smoking Status
Never 35 (7.0) 136 (26.7)
Ever 466 (93.0) 374 (73.3) < 0.001
Former 211 (45.9) 215 (59.9)
Current 249 (54.1) 144 (40.1) < 0.001
Pack-years b, mean (SD) 63.0 (36.5) 39.4 (33.3) < 0.001
Family history of cancer
No 262 (54.5) 304 (60.7)
Yes 219 (45.5) 197 (39.3) 0.049
Lung cancer 57 (12.3) 35 (7.2)
Other cancers 144 (31.1) 147 (30.5) 0.020
Histological types
Squamous cell carcinoma 202 (40.3)
Adenocarcinoma 143 (28.5)
Small cell carcinoma 81 (16.2)
Non-differentiated 37 (7.4)
Large cell carcinoma 15 (3.0)
Others 8 (1.6)
Clinical diagnosis 2 (0.4)
Missing 13 (2.6)
Clinical stages
I 126 (25.1)
II 28 (5.6)
III 119 (23.8)
IV 138 (27.5)
LS (Limited stage) 39 (7.8)
EE (Extend stage) 32 (6.4)
Missing 19 (3.8)
a Two-sided χ2 test and Mann-Whitney where appropriate
b Pack-years for ever smokersPage 4 of 12
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However, the stratified analysis [see Additional file 3]
showed that the genotype A/G was significantly associated
with an increased risk of developing lung cancer in former
smokers (adjusted OR = 1.60; 95% CI = 1.05–2.45; P =
0.030). Looking at the histological types [see Additional
file 2], the results showed a higher risk of developing
small cell lung cancer for heterozygous and homozygous
genotypes (adjusted OR = 1.94; 95% CI = 1.09–3.45; P =
0.024 and adjusted OR = 2.38; 95% CI = 1.01–5.65;P =
0.048, respectively).
Analysis of the +17 C/G polymorphism in the MMP8 gene
In the case of the +17 C/G polymorphism in MMP8, we
found that the frequency of the +17G allele was 0.130 in
our population control. Due to the low number of indi-
viduals homozygous for the G/G genotype (8 cases and 6
controls), we examined the association between the pres-
ence of the G allele and lung cancer risk (Table 3). Thus,
variant allele carriers showed a statistically significant
decreased risk for developing lung cancer (adjusted OR =
0.65; 95% CI = 0.45–0.93; P = 0.019). In the stratified
analysis we found a statistically significant decreased risk
of lung cancer in male (adjusted OR = 0.63; 95% CI =
0.43–0.93; P = 0.021), ever smokers (adjusted OR = 0.69;
95% CI = 0.48–0.97; P = 0.034), and individual with fam-
ily history of lung cancer (adjusted OR = 0.14; 95% CI =
0.03–0.64; P = 0.011) [see Additional file 4]. Looking at
histological types [see Additional file 2], we observed that
the G variant allele was significantly associated with a
decreased risk for small cell carcinoma (adjusted OR =
0.43; 95% CI = 0.20–0.89; P = 0.023) and squamous cell
carcinoma (adjusted OR = 0.51; 95% CI = 0.31–0.84; P =
0.008).
Survival Analysis
We have furthermore evaluated the progression and sur-
vival of lung cancer patients. Survival questionnaires were
collected for lung cancer patients who had been diag-
nosed at least 24 months earlier. Thus, a total of 376 eligi-
ble cases were selected until April of 2005. The overall
survival rate was 22%. We used the Kaplan-Meier survival
analysis to examine the relationship between polymor-
phisms in the promoter of the MMP genes and survival
time.
The Kaplan-Meier survival analysis in individual carriers
of the 2G allele for MMP1 not show a poorer survival sta-
tistically significant (Figure 1). In addition, the multivari-
ate analysis was used to delineate significant prognostic
factors for survival. This analysis showed that the MMP1
2G allele was not an independent prognostic factor for
overall survival after adjustment for clinical stages and
metastases (adjusted HR = 1.23; 95% CI = 0.93–1.63; P =
0.153) (Table 4) and individuals with the 2G allele does
not show a higher relative risk of death than the individu-
als with the 1G/1G genotype.
Table 3: Analysis of polymorphisms and lung cancer risk estimates
MMPs Genotype Cases
n(%)
Controls
n(%)
Adjusteda OR
[95% CI]
P P trend
MMP1 1G/1G 128 (25.5) 119 (23.3) Reference
1G/2G 248 (49.5) 259 (50.8) 0.97 [0.68–1.40] 0.884
2G/2G 125 (25.0) 132 (25.9) 1.04 [0.68–1.58] 0.859 0.857
1G/2G + 2G/2G 373 (74.5) 391 (76.7) 0.99 [0.71–1.40] 0.975 0.975
MMP8 C/C 392 (79.7) 358 (75.2) Reference
C/G + G/G 100 (20.3) 118 (24.8) 0.65 [0.45–0.93] 0.019 0.019
MMP13 A/A 248 (49.5) 267 (52.4) Reference
A/G 208 (41.5) 197 (39.4) 1.24 [0.91–1.69] 0.174
G/G 45 (9.0) 42 (8.2) 1.23 [0.72–2.11] 0.452 0.200
A/G + G/G 253 (50.5) 239 (47.6) 1.24 [0.92–1.66] 0.155 0.155
aAdjusted by age, gender, tobacco consumption (in pack-years: never, ≤ 31.5 and > 31.5), and family history of cancer
Table 4: Analysis of polymorphisms and lung cancer overall 
survival
MMPs Genotype Adjusted* HR
[95% CI]
P
MMP1 1G/1G Reference
1G/2G 1.25 [0.93–1.69] 0.143
2G/2G 1.19 [0.85–1.66] 0.312
1G + 2G 1.23 [0.93–1.63] 0.153
MMP8 C/C Reference
C/G + G/G 0.94 [0.68–1.28] 0.675
MMP13 A/A Reference
A/G 0.91 [0.68–1.22] 0.543
G/G 1.53 [0.95–2.47] 0.078
A/G + G/G 0.97 [0.76–1.23] 0.803
*Adjusted by clinical stages and metastasesPage 5 of 12
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between the A/G polymorphism in the MMP13 promoter
and survival time revealed that individual carriers of the G
allele for MMP13 showed no significant differences in sur-
vival time (Figure 2) and the multivariate analyses using
Cox's proportional hazard regression analysis did not
show statistically significant results (adjusted HR = 0.97;
95% CI = 0.76–1.23) (Table 4).
Finally, although the G allele in MMP8 showed a protec-
tive effect against the development of lung cancer, it did
not show a statistically significant protective effect associ-
ated with the survival time (P = 0.675). However, patients
who are carriers of at least one G allele not show a better
overall survival than the individuals with the C/C
homozygous genotype, although a larger sample size
would be necessary to confirm these differences (Figure
3). The multivariate analyses using Cox's proportional
hazard regression analysis did not show statistically signif-
icant results (adjusted HR = 0.94; 95% CI = 0.68–1.28)
(Table 4).
Kaplan-Meier overall survival curves of patients with lung cancer by MMP1 genotypesFigure 1
Kaplan-Meier overall survival curves of patients with lung cancer by MMP1 genotypes. The individual carriers of at 
least one 2G allele for MMP1 do not show better survival than the individual with 1G/1G homozygous genotype.
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In this study we have investigated the effect of polymor-
phisms in the promoter regions of the three human colla-
genases (MMP1, MMP8 and MMP13) and the individual
risk of developing lung cancer in a group of 501 cases and
510 controls. We have evaluated whether these polymor-
phisms could influence the progression and survival of
these lung cancer patients. Our results suggest that the
studied polymorphism in the promoter region of the
MMP8 gene is associated with lung cancer risk. Thus, indi-
viduals with at least one G variant allele showed a protec-
tive effect against developing lung cancer compared to the
reference genotype, while this polymorphism not seems
associated with a higher survival rate and a better progno-
sis. On the other hand, the studied polymorphisms in the
MMP1 and MMP13 genes do not seem to influence the
individual risk to develop lung cancer and survival time in
our population.
Our study has several strengths, including high participa-
tion of eligible cases (rate 93.8%) and quite large sample
size from a homogeneous population of similar ancestry
Kaplan-Meier overall survival curves of patients with lung cancer by MMP13 genotypesFigure 2
Kaplan-Meier overall survival curves of patients with lung cancer by MMP13 genotypes. The individual carriers of 
at least one G allele for MMP13 do not show better survival than the individual with A/A homozygous genotype.
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pathologically confirmed and finally we applied a severe
quality control for genotyping. The main limitations of
our study were hospital-based subjects, recall bias due to
the fact that information on smoking exposure was
obtained retrospectively, and especially possible false pos-
itive associations, due to the multiple comparisons made.
We cannot exclude the possibility that some of these asso-
ciations may represent chance finding, because the power
to detect interactions was limited. To minimize selection
bias, we carefully selected controls from patients admitted
for various diagnoses that were thought to be unrelated to
exposures of interest. Nevertheless, a recent paper from
Campbell et al. [36] reported that European populations
may display various levels of genetic substructure which
may lead to false positive associations due to population
Kaplan-Meier overall survival curves of patients with lung cancer by MMP8 genotypesFigure 3
Kaplan-Meier overall survival curves of patients with lung cancer by MMP8 genotypes. The individual carriers of at 
least one G allele for MMP8 do not show better survival than the individual with C/C homozygous genotype.
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ity by matching individuals on the basis of European
ancestry.
Several reports have showed that proteases from the MMP
family are implicated in tumor invasion and metastasis
due to their ability to degrade numerous components of
the extracellular matrix and basement membrane [37-39].
Focusing on lung cancer, upregulation of certain MMPs,
like MMP1 and MMP13, has been associated with the pro-
gression and poorer prognosis of squamous cell carci-
noma and adenocarcinoma [40-43], suggesting that
changes affecting the expression level of these genes could
contribute to the progression of this disease. The poly-
morphisms analyzed in this study have been previously
shown to modify the transcriptional activity of the corre-
sponding MMPs [25,44,45].
The 2G allele of the 1G/2G polymorphism in the MMP1
promoter creates an extra Ets-binding site, which results in
increased transcriptional activity of this gene [44]. Thus,
the presence of the MMP1 polymorphism has been asso-
ciated with an increased risk of developing different
human cancers including colorectal, renal and head and
neck [17,21,46]. For lung cancer, the number of studies is
still very limited. Recent studies carried out in Caucasian
and Asian populations found an association between the
2G polymorphism in the MMP1 promoter and an
increased risk of developing lung cancer [47,48]. How-
ever, and in agreement with our results, other reports
studying the 1G/2G polymorphism in larger populations
have not found an increased risk for developing lung can-
cer for the 2G allele, although stratified analysis by vari-
ous variables showed statistically significant associations
[28,49,50].
Although polymorphisms in MMP genes have been stud-
ied extensively with regard to risk of cancer, much less is
known about survival outcomes. Studies in other cancers
are provocative and suggest that some MMP polymor-
phisms may have a prognostic role. Accordingly, the 2G
allele of the MMP1 1G/2G polymorphism has been asso-
ciated with worse survival among patients with colorectal
[24] and ovarian cancer [23]. However, a study in patients
with stage I for NSCLC carrying the variant 2G allele not
showed an association between this polymorphism and
survival time [51]. Our results do not suggest an associa-
tion between this polymorphism and decreased survival
and this polymorphism is not an independent prognostic
factor of overall survival.
On the other hand, the polymorphism -77 A/G in the pro-
moter region of MMP13, which modifies a PEA3 binding
site, results in a reduced transcriptional activity of this
gene [25], which might contribute to reducing the risk of
developing cancer. However, most of the epidemiological
studies do not support this biological evidence. Two
recent studies of different types of cancer have shown no
association between the -77 A/G polymorphism and the
risk of developing breast and nasopharyngeal cancer
[26,27]. Our results constitute the first report that analyze
this polymorphism in lung cancer and suggest that the -77
A/G polymorphism in MMP13 does not contribute to the
susceptibility to develop lung cancer in the Asturian pop-
ulation. Thus, the MMP13 polymorphism does not seem
to contribute to initial stages of tumor development,
although this evidence needs to be confirmed in further
studies. Furthermore, this polymorphism doesn't appear
to have an effect on patient survival and the multivariate
analyses using Cox's proportional hazard regression anal-
ysis did not show statistically significant results. These
results don't support the biological evidence that MMP13
is implicated in tumor growth and dissemination. How-
ever, these findings need to be verified in larger clinical
studies.
In the stratified analysis by histological types, we observed
that homozygotes for variant allele of polymorphisms in
MMP1 and MMP13 genes increase the risk of developing
small cell carcinoma. Previous studies have shown that
between 70–100% of small lung carcinomas express
MMP13 and between 60–70% express MMP1 [52], which
suggests that metalloproteinases could be involved in the
initial stages of developing this histological types,
although the molecular mechanism by which they could
participate in this process is still unknown.
Contrary to results observed for polymorphisms in MMP1
and MMP13, the polymorphism studied in MMP8 was
associated with a reduced individual susceptibility to
develop lung cancer in our study. MMP8 cleaves type I col-
lagen very efficiently and is predominantly expressed and
stored in polymorphonuclear (PMN) leukocytes. The
physiological role of MMP8 is, however, still unknown.
Recent studies in animal models have shown that mutant
mice deficient in MMP8 are more susceptible to develop
skin cancer, predicting that MMP8 has a protective func-
tion against tumor developments [29,30]. In addition, a
direct anti-metastatic role for MMP8 was confirmed by
Montel et al., who found that overexpression of MMP8 in
breast cancer cell lines decreased metastases, which sug-
gests that a greater expression of MMP8 could result in a
lower incidence of cancer and a better prognosis [30]. Our
data suggest that individual carriers of the allele G in
MMP8 had lower susceptibility to develop lung cancer,
possibly due to the ability of collagenase-2 to induce anti-
metastatic processes. However, these findings need to be
verified in larger epidemiological and clinical studies. InPage 9 of 12
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ment interactions between the polymorphisms and lung
cancer risk and survival time in our population, a single
larger sample with thousands of subjects and tissue-spe-
cific biochemical and biological characterizations are
required.
Conclusion
In conclusion, this work represents the first study in which
polymorphisms in this important group of MMPs
(MMP1, MMP8 and MMP13) are analyzed together to
understand their contribution to lung cancer develop-
ment and the effect on disease progression and survival in
the Caucasian population. We attempt to contribute to
the study of useful biomarkers for screening high-risk
populations for primary prevention and early detection of
lung cancer. In the same way, as polymorphisms in the
promoter region mainly result in changes in expression, it
would be interesting to conduct a study of gene expression
to confirm our findings. Finally, the biological function of
MMPs apparently is more complex than being only
involved in growth or tumor progression [53], so further
studies would be required to elucidate the molecular
mechanisms implicated in these complex processes.
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